Interpretation of the Guidelines for diagnosis and treatment of non-tuberculous mycobacteria disease (2020 edition)

doi:10.3969/j.issn.2096-8493.2021.02.004

Abstract

Abstract:

In recent years, non-tuberculous mycobacteria (NTM) disease is increasing rapidly, which has become one of the important public health problems threatening human health and has been widely concerned. Therefore, based on the Chinese expert consensus on diagnosis and treatment of non-tuberculous mycobacteria disease, the Tuberculosis Branch of the Chinese Medical Association organized experts in related fields to develop the Guidelines for diagnosis and treatment of non-tuberculous mycobacteria disease (2020 edition) by referring to the Treatment of non-tuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline issued in 2020, the British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) issued in 2017, as well as the research achievements and diagnosis and treatment experience of NTM disease at home and abroad in recent years. The guidelines has important guiding significance for the standardization of the clinical diagnosis and treatment practice of NTM in China. In order to help the fellow peers to better understand this guideline and improve the clinical practice, the authors interpreted its main contents for reference.

Key words: Mycobacteria, atypical, Diagnosis, Treatment, Guidebooks, Comment

LIU Sheng-sheng, TANG Shen-jie. Interpretation of the Guidelines for diagnosis and treatment of non-tuberculous mycobacteria disease (2020 edition)[J]. Journal of Tuberculosis and Lung Disease , 2021, 2(2): 108-115. doi: 10.3969/j.issn.2096-8493.2021.02.004

References 31

[1]	中华医学会结核病学分会, 《中华结核和呼吸杂志》编辑委员会. 非结核分枝杆菌病诊断与治疗专家共识. 中华结核和呼吸杂志, 2012,35(8):527-580. doi: 10.3760/cma.j.issn.1001-0939.2012.08.006. doi: 10.3760/cma.j.issn.1001-0939.2012.08.006
[2]	Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J, 2020,56(1):2000535. doi: 10.1183/13993003.00535-2020. doi: 10.1183/13993003.00535-2020 URL
[3]	Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax, 2017,72(Suppl 2):ii1-ii64. doi: 10.1136/thoraxjnl-2017-210927. doi: 10.1136/thoraxjnl-2017-210927
[4]	中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020,43(11):918-946. doi: 10.3760/cma.j.cn112147-20200508-00570. doi: 10.3760/cma.j.cn112147-20200508-00570
[5]	唐神结, 高文. 临床结核病学. 2版. 北京: 人民卫生出版社, 2019: 1026-1033.
[6]	Garrity GM, Bell JA, Lilburn TG. Taxonomic Outline of the Prokaryotes. Bergey’s Manual of Systematic Bacteriology. New York, Berlin, Heidelberg: Springer, 2004: 230.
[7]	Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet, 2013,381(9877):1551-1560. doi: 10.1016/S0140-6736(13)60632-7. doi: 10.1016/S0140-6736(13)60632-7 URL
[8]	Bryant JM, Grogono DM, Rodriguez-Rincon D, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science, 2016,354(6313):751-757. doi: 10.1126/science.aaf8156. doi: 10.1126/science.aaf8156 URL
[9]	张洁, 苏建荣, 丁北川, 等. 北京地区非结核分枝杆菌菌种分布及耐药性研究. 中华结核和呼吸杂志, 2017,40(3):210-214. doi: 10.3760/cma.j.issn.1001-0939.2017.03.013. doi: 10.3760/cma.j.issn.1001-0939.2017.03.013
[10]	Wu J, Zhang Y, Li J, et al. Increase in nontuberculous mycobacteria isolated in Shanghai, China: results from a population-based study. PLoS One, 2014,9(10):e109736. doi: 10.1371/journal.pone.0109736. doi: 10.1371/journal.pone.0109736 URL
[11]	洪创跃, 李金莉, 赵广录, 等. 2013—2017年深圳市非结核分枝杆菌流行状况分析. 中国防痨杂志, 2019,41(5):529-533. doi: 10.3969/j.issn.1000-6621.2019.05.011. doi: 10.3969/j.issn.1000-6621.2019.05.011
[12]	Ruangkiattikul N, Rys D, Abdissa K, et al. Type I interferon induced by TLR2-TLR4-MyD88-TRIF-IRF3 controls Mycobacterium abscessus subsp. abscessus persistence in murine macrophages via nitric oxide. Int J Med Microbiol, 2019,309(5):307-318. doi: 10.1016/j.ijmm.2019.05.007. doi: 10.1016/j.ijmm.2019.05.007 URL
[13]	Jain D, Ghosh S, Teixeira L, et al. Pathology of pulmonary tuberculosis and non-tuberculous mycobacterial lung disease: Facts, misconceptions, and practical tips for pathologists. Semin Diagn Pathol, 2017,34(6):518-529. doi: 10.1053/j.semdp.2017.06.003. doi: 10.1053/j.semdp.2017.06.003 URL
[14]	Vande Weygaerde Y, Cardinaels N, Bomans P, et al. Clinical relevance of pulmonary non-tuberculous mycobacterial isolates in three reference centres in Belgium: a multicentre retrospective analysis. BMC Infect Dis, 2019,19(1):1061. doi: 10.1186/s12879-019-4683-y. doi: 10.1186/s12879-019-4683-y pmid: 31847834
[15]	Compton RA, Scott AR. Use of the facelift incision for excision of non-tuberculous mycobacterial lymphadenitis in children. Int J Pediatr Otorhinolaryngol, 2019,125:182-186. doi: 10.1016/j.ijporl.2019.07.005. doi: 10.1016/j.ijporl.2019.07.005 URL
[16]	Mei Y, Zhang W, Shi Y, et al. Cutaneous Tuberculosis and Nontuberculous Mycobacterial Infections at a National Speciali-zed Hospital in China. Acta Derm Venereol, 2019,99(11):997-1003. doi: 10.2340/00015555-3283. doi: 10.2340/00015555-3283 URL
[17]	Lee MR, Chien JY, Huang YT, et al. Clinical features of patients with bacteraemia caused by Mycobacterium avium complex species and antimicrobial susceptibility of the isolates at a medical centre in Taiwan, 2008-2014. Int J Antimicrob Agents, 2017,50(1):35-40. doi: 10.1016/j.ijantimicag.2017.02.016. doi: 10.1016/j.ijantimicag.2017.02.016 URL
[18]	Sardiña LA, Kaw U, Jour G, et al. Diagnosis of Mycobacterium abscessus/chelonae complex cutaneous infection: Correlation of tissue culture and skin biopsy. J Cutan Pathol, 2020,47(4):321-327. doi: 10.1111/cup.13623. doi: 10.1111/cup.13623 URL
[19]	Wetzstein N, Hügel C, Wichelhaus TA, et al. Species distribution and clinical features of infection and colonisation with non-tuberculous mycobacteria in a tertiary care centre, central Germany, 2006-2016. Infection, 2019,47(5):817-825. doi: 10.1007/s15010-019-01317-2. doi: 10.1007/s15010-019-01317-2 pmid: 31093923
[20]	中华医学会结核病学分会, 非结核分枝杆菌病实验室诊断专家共识编写组. 非结核分枝杆菌病实验室诊断专家共识. 中华结核和呼吸杂志, 2016,39(6):438-443. doi: 10.3760/cma.j.issn.1001-0939.2016.06.007. doi: 10.3760/cma.j.issn.1001-0939.2016.06.007
[21]	Richard M, Gutiérrez AV, Kremer L. Dissecting erm(41)-Mediated Macrolide-Inducible Resistance in Mycobacterium abscessus. Antimicrob Agents Chemother, 2020,64(2):e01879-19. doi: 10.1128/AAC.01879-19. doi: 10.1128/AAC.01879-19
[22]	姚岚, 郝晓晖, 唐神结, 等. 非结核分枝杆菌肺病144例的影像学特点分析. 中华结核和呼吸杂志, 2012,35(8):615-616. doi: 10.3760/cma.j.issn.1001-0939.2012.08.015. doi: 10.3760/cma.j.issn.1001-0939.2012.08.015
[23]	Boyle DP, Zembower TR, Reddy S, et al. Comparison of Clinical Features, Virulence, and Relapse among Mycobacterium avium Complex Species. Am J Respir Crit Care Med, 2015,191(11):1310-1317. doi: 10.1164/rccm.201501-0067OC. doi: 10.1164/rccm.201501-0067OC URL
[24]	Asakura T, Nakagawa T, Suzuki S, et al. Efficacy and safety of intermittent maintenance therapy after successful treatment of Mycobacterium avium complex lung disease. J Infect Chemother, 2019,25(3):218-221. doi: 10.1016/j.jiac.2018.07.021. doi: 10.1016/j.jiac.2018.07.021 URL
[25]	Swenson C, Del Parigi A. Amikacin Liposome Inhalation Suspension as a Treatment Option for Refractory Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium avium Complex. Mayo Clin Proc, 2020,95(1):201-202. doi: 10.1016/j.mayocp.2019.10.024. doi: 10.1016/j.mayocp.2019.10.024 URL
[26]	Kwak N, Dalcolmo MP, Daley CL, et al. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J, 2019,54(1):1801991. doi: 10.1183/13993003.01991-2018. doi: 10.1183/13993003.01991-2018 URL
[27]	Kang N, Jeon K, Kim H, et al. Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease. Chest, 2021:S0012-3692(21)00290-7. doi: 10.1016/j.chest.2021.02.025. doi: 10.1016/j.chest.2021.02.025
[28]	Togo T, Atsumi J, Hiramatsu M, et al. Outcomes of Surgical Treatment for Mycobacterium abscessus Complex Pulmonary Disease. Ann Thorac Surg, 2021:S0003-4975(21)00669-X. doi: 10.1016/j.athoracsur.2021.03.088. doi: 10.1016/j.athoracsur.2021.03.088
[29]	Cai SS, Chopra K, Lifchez SD. Management of Mycobacterium abscessus Infection After Medical Tourism in Cosmetic Surgery and a Review of Literature. Ann Plast Surg, 2016,77(6):678-682. doi: 10.1097/SAP.0000000000000745. doi: 10.1097/SAP.0000000000000745 URL
[30]	Griffith DE, Adjemian J, Brown-Elliott BA, et al. Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung Disease. Am J Respir Crit Care Med, 2015,192(6):754-760. doi: 10.1164/rccm.201503-0444OC. doi: 10.1164/rccm.201503-0444OC URL
[31]	Abate G, Stapleton JT, Rouphael N, et al. Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease. Clin Infect Dis, 2021,72(7):1127-1137. doi: 10.1093/cid/ciaa252. doi: 10.1093/cid/ciaa252 URL